NEWS ARCHIVE

Read More

Indica Labs 2nd London Quantitative Pathology User Meeting

HALO and HALO Link users representing a diverse set of organizations, including pharma, biotech, and academic medical centres across Europe will discuss how they are using image analysis to achieve their research objectives with an emphasis on biomarker analysis in oncology and immuno-oncology on Wednesday, November 29th 2017.

Confirmed guest speakers from CRUK/Cambridge Institute, CRUK/Beatson Institute, AstraZeneca, and University of St. Andrews. Additionally, Indica Labs will demonstrate HALO, HALO-AI and HALO Link with emphasis on new features and developments.  The audience will include both HALO/Indica Labs users as well as non-users who want to learn more about quantitative pathology from peers within UK and European academic medical centers, research institutes, and biopharma.

AGENDA

11:30 – 12:00    Registration and Lunch
12:00 – 12:40    Welcome & HALO Demonstration
12:40 – 14:10    Customer Presentations
14:10 – 14:30    Break
14:30 – 15:30    Customer Presentations
15:30 – 14:00    HALO Link Demonstration

We look forward to seeing you in London!  

While at the Congress, drop by to see us at the Indica Labs’ Booth (#6) and attend the Indica Labs’ Guest Speaker Presentation on Thursday November 30th at 15:50 – 16:20 at the Digital Pathology Congress Europe to learn more about Indica Labs’ products and services.

To register for the user meeting, email tderas@indicalab.com.

The Netherlands Cancer Institute selects the HALOTM image analysis platform to expand its immuno-oncology research capabilities

Corrales, NMOctober 24, 2017Indica Labs, the leading provider of software for quantitative evaluation of digital pathology images, is pleased to announce selection of the HALO image analysis platform by the Netherlands Cancer Institute (NKI) for in situ analysis of multiplexed biomarkers in tumor tissues.

NKI will be using the HALO platform to analyze images captured from their Perkin Elmer Vectra® 3 multispectral imaging system.   Together with the Perkin Elmer OpalTM 7 reagent kits, this system allows simultaneous detection of up to seven multiplexed protein biomarkers.  In collaboration with NKI, Indica Labs developed a method to fuse together the spectrally-unmixed field of view images generated by this platform into a single, pyramidal image of the whole tissue that can be viewed, zoomed, annotated and analyzed.  These fused images allow multiplexed biomarkers to be analyzed in the context of the whole tissue so that the spatial relationship between different cell types can be more readily evaluated, an important aspect of the immuno-oncology research being conducted at NKI.

“Our efforts in the field of multispectral imaging are part of a larger effort to better understand the biology of cancer and interactions between tumor cells, tumor surrounding stromal cells and immune cells.  Translation of our knowledge on the influence of immune cells within the tumor microenvironment is urgently needed, said Dr. Erik Hooijberg, patho-immunologist at NKI.  “To address these questions, we need to analyze multiple markers simultaneously and evaluate the interaction between different cell phenotypes in and around the tumor.”

Prof. Dr. JBAG Haanen from NKI added,  “NKI is one of the leading centers worldwide in developing biomarkers for response to immunotherapy, as exemplified by positioning of the Cancer Immunogram, a framework to describe the cancer-immune interaction at several levels. Multispectral imaging is an important asset in this endeavor.”

Indica Labs’ Chief Scientific Officer, Dr. Kate Lillard, has been working closely with Dr. Hooijberg and his colleagues at NKI to integrate the HALO image analysis platform into their multispectral imaging workflow.

“The  NKI has a strong focus on immuno-oncology which makes the work being performed here even more exciting for us,” said Dr. Lillard. “HALO has been used by other research groups to demonstrate a strong correlation between the distribution of immune cell subtypes within the tumor microenvironment and response to immunotherapy as well as patient prognosis.”  “Indica Labs is very proud that HALO is being used to progress immuno-oncology research at NKI and we believe that the discoveries being made here will lead to more treatment options and better patient care in the future.”

About The Netherlands Cancer Institute – Antoni van Leeuwenhoek (NKI-AVL)
The Netherlands Cancer Institute has been at the international forefront of cancer care and research for already more than a century. The unique combination of health care and scientific research within the same institute offers great benefits for cancer patients. Specialized cancer care professionals work together in multidisciplinary teams to set up and carry out treatment plans tailored to the needs of individual patients because no two tumors are alike. Cancer patients or people suspected of having cancer come to our hospital, known as the Antoni van Leeuwenhoek, to make use of this personalized approach and the state-of-the-art research and treatment facilities. The research institute employs more than 700 scientists investigating many aspects of cancer development, diagnosis, treatment and epidemiology. Scientists at the Netherlands Cancer Institute have access to state-of-the-art research facilities supporting their basic, translational and clinical research. This scientific research could not be carried out without the institutional support of the Dutch Cancer Society, the Ministry of Health, Welfare and Sports, the many research grants obtained by our researchers from (inter)national funding agencies, and the generous donations made by individuals that support our research program. The Netherlands Cancer Institute is the only OECI designated Comprehensive Cancer Center in the Netherlands. For more information, please visit our websites www.nki.nl and www.avl.nl.

About Indica Labs
Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images.  Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules.  Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in immuno-oncology, oncology, neuroscience, metabolism, toxicological pathology, and more.  For more information, please visit http://indicalab.com.

Upcoming Webinar – Targeting Immuno-oncology Markers in the Tumor Microenvironment – Dr. Travis Hollman, MD PhD MSKCC

Hosted by Dr. Kate Lillard Tunstall, CSO, Indica Labs, and Dr. Travis Hollmann, Memorial Sloan Kettering Cancer Center on Thursday 16th November 2017 (8 am PDT | 11 am PDT | 4 pm BST).

This two-part webinar is a must see for anyone interested in spatially-resolved multiplexing for immuno-oncology or analysis of multi-spectral images, such as the PerkinElmer Vectra® 3 or Vectra® PolarisTM platforms.

In the first half hour, Dr. Kate Tunstall from Indica Labs will give a brief introduction to HALO’s multiplex and spatial analysis tools for immuno-oncology. She will give a short demonstration of HALO, including a new tool for fusing spectrally-unmixed field of view images captured from the PerkinElmer Vectra® 3 or PolarisTM platforms into whole tissue digital slides.

Following this introduction, we welcome our invited speaker, Dr. Travis Hollmann from Memorial Sloan Kettering Cancer Center. Dr. Hollmann will discuss multiplexing initiatives at Memorial Sloan Kettering Cancer Center, including: imaging platforms used by the center, utilizing fluorescent multiplexing in immuno-oncology, image analysis using HALO High-Plex, downstream of HALO High-Plex, and technical pitfalls, future platforms and community needs.

About Dr. Hollmann
Since the late 1990’s Dr. Hollmann has been a published immunology researcher focused on understanding both innate and adaptive mechanisms of the host response as they relate to human disease. After obtaining clinical training in anatomic pathology with subspecialty boards in dermatopathology, he returned to the immunology landscape with a focus on cutaneous tumor immunology. As a Melanoma Research Alliance young investigator and as pathologist for both melanoma and lung immunotherapy Stand Up to Cancer team science team awards, he has contributed to the correlation between tumor neoantigens and patient response to immunotherapeutics. More recently, as director of Advanced Immunomorphology Platforms at MSKCC, he runs the Parker Institute for Cancer Immunotherapy Pathology laboratory at MSKCC and co-directs the GE-MSKCC in situ single cell proteomics for cancer collaboration.

Register now

Upcoming Webinar – Introducing HALO-AITM: Moving deep learning out of the computer lab and into the hands of the pathologist

Hosted by Vlado Ovtcharov, Lead Algorithm Engineer, and Dr. Kate Lillard Tunstall, CSO, Indica Labs, Inc on Wednesday 25th October 2017 (8 am PDT | 11 am PDT | 4 pm BST).

If you’ve attended any digital pathology or medical imaging meetings over the past couple of years, you have heard artificial intelligence or deep learning mentioned at least once. If you are not a computer scientist, algorithm engineer or image analyst, you might be wondering how these tools differ from all the other image analysis and pattern recognition tools that have been used in digital pathology for years. In this webinar, we will demystify this emerging technology with a bit of background, explain its current and potential applications in pathology and discuss how the Indica Labs’ HALO-AITM platform is making this powerful technology accessible to the pathology community.

Register now

University of Cambridge Laboratories select HALO AITM deep learning technology to advance metabolic disease research

Corrales, NM – October 5, 2017 – Indica Labs Inc headquartered in Corrales, New Mexico, is pleased to announce the selection of the newly developed deep learning classification tool, HALO AITM, by the University of Cambridge Metabolic Research Laboratories (MRL) in England.

HALO AI or ‘Artificial intelligence’ is a convolutional neural network platform resulting from years of effort by the Indica Labs’ research & development team, whose goal was to build a deep learning tool that could decipher and assess the complex patterns of histologically stained tissues, in a similar way to the brain of the pathologist. HALO AI was put to the test earlier this year in the Camelyon 17 challenge to determine TNM staging in 100 breast cancer patients where it scored highest amongst all commercial participants.
HALO AI will be used within the Metabolic Research Labs Imaging Core at the Welcome Trust-MRC, Institute of Metabolic Science. The decision of the MRL to acquire HALO AI came after an extensive evaluation through a series of proof-of-concept studies, including the evaluation of necrosis and inflammation in acute liver damage, measurement of placental zones during different stages of gestation, and detection of glomeruli in kidney tissue (as shown above).

“Image analysis is now moving towards machine learning and deep neural network algorithms and we would like to be at the forefront of these emerging developments,” said Gregory Strachan of the University of Cambridge. “We expect the Indica Labs’ HALO AI classifier to be an important new tool in our Translational Research Facility, opening up high-throughput analysis and more accurate tissue classification. Combined with HALO’s powerful analysis tools on whole tissue slide images, we should be able to deliver robust results much more quickly.”

Indica Labs CEO, Steven Hashagen, added, “Artificial intelligence is moving medical imaging into an exciting new era and digital pathology is no exception. We know that the earlier adopters like the University of Cambridge MRL will push out the boundaries with HALO AI to discover applications for this emerging technology that we never imagined. We are incredibly excited to see what advances come from this collaboration.”

Funding for purchase of HALO AI was provided by the Wellcome Trust Strategic Award [100574/Z/12/Z].

About the University of Cambridge Metabolic Research Laboratories (MRL)
The MRL brings together outstanding scientific and clinical researchers from 23 laboratories to form an international centre of excellence for research into metabolism and metabolic disease. MRL scientists collaborate to improve understanding, prevention and treatment of diabetes, obesity and other related endocrine and metabolic disorders, and to develop treatments for these conditions. The MRL is the base for the Medical Research Council (MRC) Metabolic Diseases Unit, which was awarded in 2013 as part of a strategic funding partnership between Wellcome and the MRC. http://www.mrl.ims.cam.ac.uk/

About Indica Labs
Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images. Indica Labs’ HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules. Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in immuno-oncology, oncology, neuroscience, metabolism, toxicological pathology, and more. For more information, please visit http://indicalab.com

MolecularMD Announces Partnership with Indica Labs to Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services

Portland, OR – September 29, 2017 – MolecularMD, a provider of molecular and tissuebased clinical trial assays and diagnostics for oncology based drug development programs, has announced a partnership agreement with Indica Labs, a leader in digital pathology imaging tools and services. The collaboration between the companies leverages MolecularMD’s diagnostic clinical testing solutions with Indica Labs’ digital biomarker analysis services to enable an efficient transition of pre-clinical research to the diagnostic setting and deployment of advanced image analysis workflows. Mindful that many of its clients are using Indica Labs’ products and services, MolecularMD envisions the partnership will facilitate seamless transition of image analysis methods to the clinical trial setting for accelerated drug development programs.

“Indica Labs’ HALOTM image analysis software and the HALO LinkTM image management system provides advanced image analysis capabilities in a global collaborative environment,” said Doug Bowman, Vice President of Pharma Services at Indica Labs. “This agreement will allow our clients to take advantage of MolecularMD’s capabilities, and MolecularMD’s clients to develop quantitative assays to better understand biomarker expression levels and spatial relationships relative to the tissue microenvironment.”

“The agreement will provide our clients with integrated genomic and phenotypic biomarker analyses that are crucial for accurate and effective patient stratification,” said Dan Snyder, President and Chief Executive Officer at MolecularMD.

“Indica Labs fills our clients’ needs for digital biomarker analysis and enhances our proposition to immuno-oncology development programs. These capabilities will provide unique advantages and accelerate pipeline decisions. The use of advanced algorithms for IHC data interpretation holds the possibility of improved patient outcomes,” said Snyder.

Indica labs will attend the Pathology Visions 2017 Conference, a conference that brings together the luminaries and key opinion leaders in digital pathology. More information about the partnership can be found at the Indica Labs Booth #7. Pathology Visions 2017 will be held from October 1-3, 2017 in San Diego at the Manchester Grand Hyatt. For more information about Pathology Visions 2017, click here.

About Indica Labs
Indica Labs is the first company to offer tissue specific and application specific image analysis algorithms in a truly integrated digital pathology environment. Pharmaceutical, healthcare, and research organizations worldwide utilize Indica tools for highthroughput, whole-slide image quantification in areas such as neuroscience, metabolism, oncology, toxicological pathology, and more. Learn more at www.indicalab.com.
Contact Information: Douglas Bowman, VP of Pharma Services (dbowman@indicalab.com)

About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular and tissue diagnostics for oncology drug development. Diagnostic assays are designed to enable appropriate selection, monitoring and management of patients treated with targeted and immune-based cancer therapies. MolecularMD integrates gold-standard and innovative platform technologies with clinical assay design, validation, and design control and leverages a comprehensive quality management system to accelerate all phases of oncology clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel therapies. Learn more at www.molecularmd.com.
Contact Information: Tina Beauchemin (Tbeauchemin@molecularmd.com)

Indica Labs Appoints a Vice President, Pharma Services

Dr. Keith J. Kaplan | July 31, 2017  | Source: Indica Labs

Indica Labs announced today that Douglas Bowman has been appointed Vice President, Pharma Services. Mr. Bowman will play an important role as the company develops its image analysis and biomarker assay services business to support preclinical and clinical biomarker assays for Indica Lab’s academic, biotech, and pharma customers.

Doug was previously at Takeda Pharmaceuticals for 11 years where he was responsible for developing quantitative biomarker assays to support the Oncology Discovery and Translational Research groups. He was a key contributor to the development of a high throughput, automated, IHC biomarker laboratory that integrated a sample management system, digital slide scanners, and quantitative image analysis into the research workflow. “I am excited at the opportunity to utilize our application expertise and industry-leading software platforms to provide image analysis and biomarker analysis services to our customers,” said Mr.Bowman. “I am confident these services will both alleviate resourcing pressure while enabling our customers to further their research and drug discovery programs by providing a better  understanding of the biomarkers within the tissue environment.”

Indica Labs’ CEO, Steven Hashagen remarked, “We are delighted to welcome Doug to the team.  He is recognized as a key opinion leader in the oncology biomarker domain and will be a  tremendous asset to our Pharma Services team.  Under his leadership we expect this strategic business unit to experience continued growth.”

About Indica Labs, Inc.

Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images. Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules. Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in immuno-therapy, oncology, metabolism, toxicological pathology, neuroscience and more. For additional information, please visit http://www.indicalab.com.

Read more: http://tissuepathology.com/2017/07/31/indica-labs-appoints-a-vice-president-pharma-services/#ixzz4pHo7qOJO

 

HALO® Deep Learning Technology Awarded for Automated Breast Cancer Metastasis Staging

Corrales, NM – April 24th 2017 – Indica Labs proudly announces its breakthrough HALO® Deep Learning technology excelled in the CameLyon17 diagnostic image analysis competition.  The international challenge engaged commercial and academic teams worldwide to develop deep-learning algorithms to analyze 500 whole-slide H&E lymph node images and calculate TNM staging of 100 breast cancer patients. The HALO Deep Learning solution was the highest ranking commercial solution and third overall among 32 accepted teams.

Indica’s CEO Steven Hashagen remarked “Our team is excited to learn the results of the competition. Cancer staging is critical for determining a patient’s prognosis and treatment, yet it is a very complex task for both machine and pathologist. Our HALO platform is at the forefront of cancer research, cancer diagnostics, and improvement of patient outcome, yet we’re just scratching the surface of what will be accomplished with the technology.

The HALO Deep Learning system combines multiple Neural Network technologies which are seamlessly integrated into HALO, the industry-leading digital pathology platform. Indica Labs has rolled out beta-evaluations of the technology to several pharmaceutical companies, academic medical centers, and the National Cancer Institute.  Official launch of the product is scheduled for July 2017.  Deployment options include both cloud-based and on-premise configurations.

Full results and details of the CameLyon17 competition can be found at https://camelyon17.grand-challenge.org/results/.  For more information, evaluation, and collaboration opportunities, please contact us at info@indicalab.com.

 

About Indica Labs, Inc.

Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images.  Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules.  Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in immuno-therapy, oncology, metabolism, toxicological pathology, neuroscience and more.

Indica Labs opens office in Tokyo to provide dedicated support to customers in Japan インディカ・ラボ社 国内拠点新設について

Tokyo, 9 January, 2017 – Indica Labs expanded its international presence again this month with the establishment of a new office in Tokyo, Japan and the recruitment of Hideya Makino to manage Japanese operations.  Mr. Makino has over 14 years of combined experience in the fields of microscopy, digital pathology and image analysis gained through his previous positions at Roche, Leica, Aperio, and Roper Technologies.

Indica Labs’ has been steadily growing its global business since 2012.  In addition to Tokyo, Indica Labs has representatives based in the United Kingdom and in the United States who provide dedicated support to customers in Europe and North America, respectively.

“Indica Labs is committed to providing superior service and support to all of our customers,” said Steven Hashagen, CEO of Indica Labs.  “In the last two years, the adoption of Indica Labs’ products in Asia, and especially in Japan, has risen dramatically.  Having local representatives [in Japan] who are dedicated to our products and who can respond to customers in a timely manner and in the local language is essential for providing top quality support to this growing customer base.  We are pleased to have Makino-san leading this effort on behalf of Indica Labs in Japan.”

Customers in Japan with sales and support inquires, can contact Indica Labs by phone (+81 (0)70 4180 7730) or email (hmakino@indicalab.com).

About Indica Labs, Inc.

Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images.  Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules.  Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in neuroscience, metabolism, oncology, toxicological pathology, and more.  For more information, please visit http://indicalab.com.

2017年1月9日

Indica Labs Inc.(本社・アメリカ、以下インディカ・ラボという)は今月から日本におけるカントリーマネージャーとして牧野英哉を採用し、東京に新たな拠点を設けることで、国際的なプレゼンスを継続的に拡大していきます。牧野はこれまでRoche、Leica、Aperio、Roper Technologiesといった前職で得られた計14年以上の経験をもとに、顕微鏡、デジタル病理学、画像解析の分野における実績を積み重ねてきました。
インディカ・ラボは2012年以来、着実にグローバルビジネスを展開しています。東京に加えて、これまで英国および米国に拠点を置き、既にヨーロッパおよび北米の顧客に向け専門的なサポートを提供しています。
インディカ・ラボのCEO、Steven Hashagenは次のように述べています。
「インディカ・ラボは、すべてのお客様に優れたサービスとサポートを提供することを約束しています。過去2年間、アジア、特に日本でのインディカ・ラボの製品の採用は劇的に増加しました。私たちの製品に特化し、タイムリーに、そして現地語で顧客に対応できる代表者の存在は、この成長する顧客基盤に最高品質のサポートを提供するために不可欠です。日本におけるIndica Labsを代表して牧野氏がこの取り組みを指揮してくれることを嬉しく思っています」
販売およびサポートに関するお問い合わせがある場合は、電話(070-4180-7730)または電子メール(hmakino@indicalab.com)でインディカ・ラボにご連絡ください。

<Indica Labs Inc.について>
Indica Labs Inc.は、デジタル病理画像の定量的評価のためのソフトウェアの大手プロバイダーです。 インディカ・ラボのHALO™画像解析プラットフォームは、業界をリードする幅広いアプリケーション特有の画像解析モジュールの基盤となる、精度、性能、スケーラビリティ、ユーザビリティの独自性の高い組み合わせを持つサービスをご提供いたします。世界中の医薬品および医療研究機関で、神経科学、代謝、腫瘍学、毒物学的病理学などの組織ベースの研究プログラムをサポートするためにHALOを利用しています。
詳細については、http://indicalab.com/ をご覧ください。

Indica Labs invites you to Cruise Chicago with us

Indica Labs, in conjunction with Global Engage Digital Pathology Congress 2017, formally invites you to take in a unique view of the Chicago Skyline while enjoying dinner and drinks with your conference delegates as you cruise the Chicago River on this 90 ft luxury yacht!

Event Date
Sunday, July 9th, 2017

Event Times
6:00 PM                    Guest Loading
6:30 PM Prompt      Yacht Departure for Sunset Cruise – Dinner & Drinks will be served
8:30 PM                    Yacht Returns to Harbor & Guest Depart Ship

Event Location
Anita Dee I Yacht at DuSable Harbor
200 N Breakwater Access
Chicago, IL 60601

Transportation
Starting at 5:30 PM – there will be a shuttle taking guests from the Palmer House Hilton Hotel to the Harbor, and returning guests to the hotel at the end of the cruise

Parking
For guests who choose to drive, there is parking available at the DuSable Harbor Parking Lot – rates range from $16-$24

RSVP by Wednesday July 5th
Email your Full Name, Company & Title to marketing@indicalab.com to RSVP for this Exclusive Dinner Event.

 

 

Indica Labs advance immuno-oncology capabilities with innovative quantification of multiplexed chromogenic immunohistochemistry

Corrales, NM – 2 November, 2016 – Indica Labs, a leading provider of software for quantitative evaluation of digital pathology images, is pleased to announce the release of a new module for multiplex chromogenic IHC analysis using HALO™.  The Multiplex IHC module can separate up to five stains simultaneously and analyze any subcellular compartment, nucleus, cytoplasm or membrane, making it ideally suited for applications in immuno-oncology where multiple markers are required to characterize distinct immune and tumor cell populations within the tissue.

Due to limitations with traditional color deconvolution, digital pathology image analysis has been largely limited to single or dual immunohistochemistry and analysis of more than two stains could only be accomplished using serial section alignment or immunofluorescence and fluorescence slide scanning.   The Multiplex IHC overcomes these barriers using advanced color unmixing and cell segmentation protocols to facilitate multiplex analysis from a single slide without the need for expensive, time-consuming fluorescent image capture or serial section analysis.  Using fast brightfield whole-slide image acquisition and analysis, Multiplex IHC paves the way for more rapid, cost effective multiplex biomarker evaluation.  An example of 4-plex IHC analysis is shown in figure below.


4-way color decnvolution

Figure 1. 4-plex IHC stained tissue (A). With advanced color deconvolution using HALOs Multiplex IHC module, we can visualize (B) hematoxylin counterstain (C) brown nuclear marker, (D) blue membrane marker, and (E) pink/red cytoplasmic marker. The positivity of each marker is measured in each subcellular compartment based on user-determined thresholds and the resulting mark-up image is shown in (F). Advanced staining courtesy of the Trev and Joyce Deeley Research Centre, BC Cancer Agency


Indica Labs, CEO, Steven Hashagen commented, “HALO product development has always been driven by customer needs and the Multiplex IHC module is no exception.  Chromogenic multiplexing has become increasingly more important in immuno-oncology, and our revolutionary color deconvolution technology opens many doors in this area.”

To request a live demonstration, software trial or upgrade to your existing HALO platform, please contact us at info@indicalab.com.

About Indica Labs, Inc. 

Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images.  Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules.  Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in neuroscience, metabolism, oncology, toxicological pathology, and more.  For more information, please visit http://indicalab.com.

 

 

November 15th Webinar: Introducing HALO Link, Collaborative Pathology Information System

Indica Labs invites you to attend our November webinar:

Introducing HALO Link, Collaborative Pathology Information System

Tuesday November 15th | 8 AM PST | 11 AM EST | 4 PM GMT
Presented by Kate Tunstall Ph.D, CSO

Designed with image analysis users in mind, Indica Labs introduces HALO LinkTM, a collaborative digital pathology information system which integrates seamlessly with the HALOTM image analysis platform.  In this 45-minute webinar, we will demonstrate how HALO Link can be used to:
Organize whole slide images into studies and grant collaborators remote access to studies using role-based sharing
Automate data entry with barcodes and integration to external databases
View, annotate and run analysis on whole slide images outside of HALO using an advanced browser-based viewer
Perform quality control on your analysis results and view trends across slides using integrated plots

 

Register Now

You’re Invited to our European Quantitative Pathology Meeting

You’re Invited

 Indica Labs would like to formally invite you to our European Quantitative Pathology Meeting in London which will be held on Wednesday 30th November from 12:00-5 PM at the London Marriott Heathrow Hotel.

Customer presenters representing diverse organizations,including pharma, biotech, and academic medical centres across Europe will discuss how they are using HALO image analysis to achieve their research objectives with an emphasis on biomarker analysis in oncology, particularly immuno-oncology. Additionally, there will be presentations from Indica Labs introducing new features in HALO and STRATA and a demonstration of our new data management platform, HALO Link.

You do not need to be a current HALO user or Indica Labs customer to attend.  We welcome anyone who is interested in learning more about HALO quantitative pathology from their peers to register for the meeting.

Presenters

Speaker Grid (2)

Users can register by emailing Liz Amdahl, liz@indicalab.com

This meeting is being held in conjunction with the Digital Pathology Congress at the same venue; however, attendance at the user group does not require registration for the congress.

 

 

Webinar September 28th | Evaluating Immune Checkpoint Biomarkers in Melanoma using HALO and STRATA

Case Study using HALO™ and STRATA™:
Biomarkers of Anti-tumor Immune Activity Associate with Survival in Melanoma

Wednesday Septmber 28th | 8 AM PDT | 11 AM EDT | 4 PM BST
Presenters
Dr. Tricia Cottrell, Johns Hopkins Medical School 
Vlado Ovtcharov, Indica Labs

PD-L1 expression in the tumor microenvironment can be both prognostic and predictive.  PD-L1 expression is often a marker of an ongoing CD8+ cytotoxic T-cell-mediated anti-tumor immune response, and thus, patients with PD-L1-positive melanomas have improved overall survival relative to those with PD-L1- negative melanomas. PD-L1 expression and high CD8-T-cell density have also been associated with an increased probability of response to PD-1 pathway blockade therapies in melanoma.

In this webinar, Dr. Cottrell and Mr Ovtcharov will describe recent studies using digital image analysis with Indica Labs’ HALOTM and STRATATM platforms to characterize immunohistochemical features of the tumor microenvironment and correlate them with survival for patients with melanoma.

Register Here 


Dr. Cottrell’s Bio

Dr. Tricia Cottrell from Johns Hopkins School of Medicine is a post-doctoral fellow in the lab of Dr. Janis Taube.  Dr. Taube’s laboratory described PD-L1-mediated adaptive immune resistance by melanoma, a finding that has now been extended to other tumor types. She also developed a robust immunohistochemistry assay and interpretation methods for studying PD-L1 as it relates to therapeutic response.  Versions of this assay are now approved by the U.S. Food and Drug Administration for clinical use.  Dr. Cottrell’s work in the Taube lab focuses on the use of digital image analysis platforms for quantitative characterization of biomarkers in the tumor microenvironment for improve prognostic and predictive applications.

 

 

 

Join Indica Labs at the 2nd Digital Pathology Congress in Philadelphia

Indica Labs’ Sales Application Scientist Adam Smith will be presenting on the STRATA Platform July 14th from 11:45-12:15 at the 2nd Digital Pathology Congress in Philadelphia. His presentation will focus on the connection of Image Analysis resulting in the collection of millions of data points and data point combinations. STRATA provides a connection between this image analysis data and patient data in order to determine how these two data silos are correlated. From these correlations we can use STRATA to QC data, identify/optimize cut points, and create predictive classifiers of patient response. Please stop by our booth #5 for a further demonstration of STRATA, and as well as, HALO 2.0.

ACD and Indica Labs Present a Joint Webinar Event

Current State-of-the-Art Tissue-Based RNA Analysis with RNAscope Technology and Quantitative Analysis with the HALO Image Analysis Platform 

June 1st, 2016, 8 am PDT | 11 am EDT | 4 pm BST (GMT+1)

Advanced Cell Diagnostics’ RNAscope® platform is fast becoming a routinely used method for target validation and biomarker development based on in situ gene expression analysis. ACD has nearly 9000 target RNA-specific probes in use and there are over 400 publications with the method. RNAscope® technology enables faster and more rigorous target and biomarker development: it is a robust and ultra-sensitive RNA in situ hybridization (RNA ISH) method providing single-cell and single-molecule RNA detection in the context of complex tissue microenvironments. In this webinar the RNAscope® technology and published applications will be presented by ACDBio.  Quantitative analysis of single/dual chromogenic probes and multiplex fluorescent probes using the HALO platform will be demonstrated by Indica Labs.

Presenters:
Courtney Anderson, PhD- Senior Scientist, R&D, ACDBio
Sean Griffiths, PhD- Application Scientist, Indica Labs 

Webinar: Introducing Strata

Introducing STRATATM| Mining tissue-based analysis data to identify predictive and/or prognostic factors using STRATA, an integrated tissue informatics platform 

May 3rd, 2016, 8 am PDT | 11 am EDT | 4 pm BST (GMT+1)

 

Combining multiplexed, spatially-resolved analysis capabilities with the fastest processing speeds in the industry, Indica Labs’ HALO™ analysis platform allows scientists to quickly generate vast amounts of biomarker expression data from large patient populations.  As the volume of analysis data increases, the challenge shifts from data collection to data mining. In this 30-minute webinar, Indica Labs introduces STRATA™, a new platform for visualizing, managing and mining biomarker analysis data to identify end points associated with patient outcomes.

Hosted by Dr. Kate Lillard Tunstall, PhD, CSO Indica Labs

REGISTER HERE  

More info about STRATA

Indica Labs announce release of HALO 2.0

Corrales, NM – 11 April, 2016 – Indica Labs, a leading provider of software for quantitative evaluation of digital pathology images, is pleased to announce the latest release of its flagship image analysis platform, HALOTM.  Established as the industry’s fastest and most user-friendly analysis platform, HALO 2.0 adds new capabilities, support for new file formats, and even greater ease-of-use.

Those familiar with HALO will recognize the new, more modern look-and-feel of HALO 2.0 including interchangeable dark and light skins designed to ease eye-strain when working with darkfield and brightfield images.  While this is the most obvious change, improvements are much more than skin deep.  HALO 2.0 adds a new tuning interface to make analysis set-up even easier, the ability to create spatial plots, heat maps, and histograms from any HALO analysis result, and tools for data import/export, sharing, archiving, and report generation.

New modules are also available with HALO 2.0, including spatial analysis and high-plex FL.  Particular important for those conducting immuno-oncology and angiogenesis research, the spatial analysis module is actually a suite of tools for analysing proximity and relative spatial distribution of objects, cells and/or features across single tissues or serial sections.  The high-plex FL module allows for simultaneous analysis of up to 8 markers and can be used in conjunction with most fluorescent whole-slide image format, including newly added support for multispectral floating-point qptiff images and whole-slide images produced from the Perkin-Elmer Vectra® 3 platform.

“Driven by our commitment to customer-centric product development, HALO has evolved rapidly and, in a relatively short space of four years, has become the image analysis platform of choice by 10 out of the top 12 pharmaceutical companies and hundreds of pathology labs worldwide,” says Steven Hashagen, CEO of Indica Labs, “With HALO 2.0, we are again improving ease-of-use while at the same time incorporating new features requested by the HALO community.”

Please follow this link  to view our recent webinar covering some of the new features in HALO 2.0.  To request a live demonstration, software trial or upgrade to your existing HALO platform, please contact us at info@indicalab.com.

 

About Indica Labs, Inc.

Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images.  Indica Lab’s HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules.  Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in neuroscience, metabolism, oncology, toxicological pathology, and more.  For more information, please visit http://indicalab.com.

Inaugural East Coast HALO User Group to be held in Cambridge, MA on February 11, 2016

 

Indica Labs would like to formally invite you to the Inaugural East Coast HALOTM User Group Meeting which will be held on 11th February, 2016 from 1- 5 PM at the Boston Marriott Cambridge, Kendall Square. Lunch (12-1 PM) and happy hour refreshments (5-6 PM) will be available to all registered attendees. Both current HALO users and those interested in learning about HALO and other Indica Labs software are welcome to attend and participate.

Indica Labs CSO, Dr. Kate Lillard, and East Coast Application Scientist, Adam Smith, will demonstrate some of the new features in HALO and introduce a completely new software platform. Additionally, we are pleased to have the following local HALO users presenting at the meeting:

 

alnylamcircle1Dr. Kristina Perry

Scientist
Drug Safety and Metabolism
Alnylam Pharmaceuticals

 

 

jimround1Jim Deeds

Senior Technical Leader
Oncology Targets & Biomarkers
Novartis | NIBR

 

chandracircle1Dr. Chandra Saravanan

Molecular Pathologist
Novartis | NIBR

 

 

alexround1Dr. Alexander Klimowicz

Principal Scientist, Immunology and Inflammation Research
Boehringer Ingelheim

 

 

To register your interest in attending this event, please email your contact details to Elizabeth Amdahl, liz@indicalab.com.

We look forward to seeing you at the meeting!

Boehringer Ingelheim Principal Scientist Alex Klimowicz and Indica Labs CSO Kate Lillard to present at Pathology Visions Boston

 

Discoveries from the field:  Expediting drug developments and clinical trials with digital pathology and HALO image analysis

Alex Klimowicz, PhD, Principal Scientist, Boehringer Ingelheim Pharmaceuticals

Kate Lillard Tunstall, PhD, CSO, Indica Labs

 

In this 60-minute presentation, our speakers will detail how the HALO image analysis platform has been used to analyze biomarkers in translational research and drug development, respectively. So please join us October Tuesday 13th at 8 a.m. in the Carlton Ballroom at the Westin Waterfront Hotel, at the Pathology Visions Conference.

Supported File Formats:


  • – Non Proprietary (JPG, TIF)
  • – 3D Histech (MRXS)
  • – Aperio (SVS, AFI, eSlideManager)
  • – Hamamatsu (NDPI, NDPIS)
  • – Leica (SVS, SCN, LIF)
  • – Mikroscan (TIF)
  • – Nikon (ND2)
  • – Olympus (VSI)
  • – Perkin Elmer (QPTIFF, Vectra TIF)
  • – Philips IMS
  • – Zeiss (CZI)

Don’t see the format you’re looking for? Contact us to make a request

CLOSE
Thank you for signing-up. Please check your email for link to access webinar recording.